Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Cited by (883)

Items 101–200 of 883

1. Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity
   Katherine Hsin-Yu Chau, Ajay Jayant Kirtane, Rachel M. Easterwood, Björn Redfors, Zixuan Zhang, Bernhard Witzenbichler, Giora Weisz, Thomas Stuckey, Bruce R. Brodie, Michael J. Rinaldi et al. · 2021 · JACC: Cardiovascular Interventions
2. Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis
   Henri M.H. Spronk, Teresa Padró, Joylene E. Siland, Jürgen H. Prochaska, Joris Winters, Allard C. van der Wal, Jelle J. Posthuma, Gordon D O Lowe, Elisa D’Alessandro, Philip Wenzel et al. · 2018 · Thrombosis and Haemostasis
3. Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity
   Abhishek Joshi, Lukas Emanuel Schmidt, Sean A. Burnap, Ruifang Lu, Melissa V. Chan, Paul C. J. Armstrong, Ferheen Baig, Clemens Gutmann, Peter Willeit, Peter Santer et al. · 2021 · Arteriosclerosis Thrombosis and Vascular Biology
4. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?
   Dietmar Trenk, Karsten Schrör, Meinrad Gawaz, Steen Dalby Kristensen, Robert F. Storey, Kurt Huber, Jolanta Maria Siller-Matula, for the European Platelet Academy · 2014 · Thrombosis and Haemostasis
5. Effect of Adjusted Antiplatelet Therapy on Preventing Ischemic Events After Stenting for Intracranial Aneurysms
   Wenqiang Li, Wei Zhu, Anxin Wang, Guojun Zhang, Yisen Zhang, Kun Wang, Ying Zhang, Chao Wang, Limin Zhang, Hui Zhao et al. · 2021 · Stroke
6. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness
   Nikolaos Kakouros, Thomas S. Kickler, Katherine Laws, Jeffrey J. Rade · 2013 · Journal of Thrombosis and Haemostasis
7. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing
   Susanne C. Gruber, Erik Lerkevang Grove, Thomas Werner Weiss, Johann Wojta, Kurt Huber, Matthias Karl Freynhofer · 2015 · Thrombosis and Haemostasis
8. State of the Art in Platelet Function Testing
   Beate E. Kehrel, Martin F. Brodde · 2013 · Transfusion Medicine and Hemotherapy
9. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: Post-hoc analysis of the randomized PRASFIT-ACS study
   Masato Nakamura, Takaaki Isshiki, Takeshi Kimura, Hisao Ogawa, Hiroyoshi Yokoi, Shinsuke Nanto, Morimasa Takayama, Kazuo Kitagawa, Yasuo Ikeda, Shigeru Saito · 2015 · International Journal of Cardiology
10. Aspirin unresponsiveness predicts thrombosis in high-risk pediatric patients after cardiac surgery
    Sirisha Emani, Bethany P. Trainor, David Zurakowski, Christopher W. Baird, Francis Fynn‐Thompson, Frank A. Pigula, Sitaram M. Emani · 2014 · Journal of Thoracic and Cardiovascular Surgery
11. Platelet Function Profiles in Patients with Diabetes Mellitus
    Fabiana Rollini, Francesco Franchi, Ana Muñiz‐Lozano, Dominick Joseph Angiolillo · 2013 · Journal of Cardiovascular Translational Research
12. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials
    Sripal Bangalore, Amita Singh, Bora Toklu, James J. DiNicolantonio, Kevin Croce, Frederick Feit, Deepak L. Bhatt · 2014 · Open Heart
13. High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization
    Gilles Montalescot, Grégoire Rangé, Johanne Silvain, Jean‐Louis Bonnet, Ziad Boueri, Olivier Barthélémy, Guillaume Cayla, Loïc Belle, Eric VAN BELLE, Thomas Cuisset et al. · 2014 · Circulation
14. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial
    Dániel Aradi, Lisa Groß, Dietmar Trenk, Tobias Geisler, Béla Péter Merkely, Róbert Gábor Kiss, András Komócsi, Csaba András Dézsi, Zoltán Ruzsa, Imre Ungi et al. · 2019 · European Heart Journal
15. Personalised antiplatelet therapies for coronary artery disease: what the future holds
    Davide Capodanno, Dominick Joseph Angiolillo · 2023 · European Heart Journal
16. Routine Assessment of On-Clopidogrel Platelet Reactivity and Gene Polymorphisms in Predicting Clinical Outcome Following Drug-Eluting Stent Implantation in Patients With Stable Coronary Artery Disease
    Chiara Viviani Anselmi, Carlo Briguori, Roberta Roncarati, Laura Papa, Gabriella Visconti, Amelia Focaccio, Francesca De Micco, Michael V.G. Latronico, Paolo Antonio Pagnotta, Gianluigi Condorelli · 2013 · JACC: Cardiovascular Interventions
17. Personalized antiplatelet therapy with P2Y 12 receptor inhibitors: benefits and pitfalls
    Max‐Paul Winter, Marek Koziński, Jacek Kubica, Dániel Aradi, Jolanta Maria Siller-Matula · 2015 · Advances in Interventional Cardiology
18. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis
    Anne H. Tavenier, Roxana Mehran, Mauro Chiarito, Davide Cao, Carlo Andrea Pivato, Johny Nicolas, Frans Beerkens, Matteo Nardin, Samantha Sartori, Usman Baber et al. · 2021 · European Heart Journal - Cardiovascular Pharmacotherapy
19. Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis
    Maria Giulia Battelli, S. Musiani, Laura Buonamici, Spartaco Santi, Massimo Riccio, Nadir M. Maraldi, Tomás Girbés, Fiorenzo Stirpe · 2004 · Cellular and Molecular Life Sciences
20. New Approaches to Inhibiting Platelets and Coagulation
    Jeremiah Peter Depta, Deepak L. Bhatt · 2015 · The Annual Review of Pharmacology and Toxicology
21. How I use laboratory monitoring of antiplatelet therapy
    Alan D. Michelson, Deepak L. Bhatt · 2017 · Blood
22. Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST (II Edição, 2007) - Atualização 2013/2014
    José Carlos Nicolau, Ari Timerman, José Antônio Marin‐Neto, Leopoldo Soares Piegas, C.J.C.B Dornas, André Franci, A Avezum, ACC Carvalho, Brivaldo Markman Filho, Carísi Anne Polanczyk et al. · 2014 · Arquivos Brasileiros de Cardiologia
23. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors
    Max‐Paul Winter, Erik Lerkevang Grove, Raffaele De Caterina, Diana Adrienne Gorog, Ingo Ahrens, Tobias Geisler, Paul Alfred Gurbel, Udaya S. Tantry, Eliano Pio Navarese, Jolanta Maria Siller-Matula · 2017 · European Heart Journal - Cardiovascular Pharmacotherapy
24. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations
    Mattía Galli, Francesco Franchi, Fabiana Rollini, Larisa H. Cavallari, Davide Capodanno, Filippo Crea, Dominick Joseph Angiolillo · 2021 · Expert Review of Clinical Pharmacology
25. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity
    Pierre Deharo, Jacques Quilici, Laurence Camoin‐Jau, Tom Johnson, Clémence Bassez, Guillaume Bonnet, M. Juárez Fernández, Manal Ibrahim, Pierre Suchon, Valentine Verdier et al. · 2017 · JACC: Cardiovascular Interventions
26. Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective
    Antonio Mangieri, Francesco Gallo, Alessandro Sticchi, Arif Azhar Khokhar, Alessandra Laricchia, Francesco Giannini, Antonio Colombo · 2020 · Cardiovascular Intervention and Therapeutics
27. Single or dual antiplatelet therapy after PCI
    Yosuke Miyazaki, Pannipa Suwannasom, Yohei Sotomi, Mohammad Abdelghani, Karthik Tummala, Yuki Katagiri, Taku Asano, Erhan Tenekecioğlu, Yaping Zeng, Rafael Cavalcante et al. · 2017 · Nature Reviews Cardiology
28. Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting
    Mathieu Pankert, Jacques Quilici, Anderson Loundou, Valentine Verdier, Marc Lambert, Pierre Deharo, Guillaume Bonnet, Bénédicte Gaborit, Pierre‐Emmanuel Morange, René Valéro et al. · 2013 · The American Journal of Cardiology
29. Pharmacogenetics of Antiplatelet Therapy
    Matteo Castrichini, Jasmine A. Luzum, Naveen L. Pereira · 2022 · The Annual Review of Pharmacology and Toxicology
30. A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users
    Ruben L.J. Osnabrugge, Stuart J. Head, Felix Zijlstra, Jurriën M. ten Berg, M. G. Myriam Hunink, A. Pieter Kappetein, A. Cecile J.W. Janssens · 2014 · Genetics in Medicine
31. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel
    Pierre Fontana, Willibald Hochholzer, Franz‐Josef Neumann, Jurriën M. ten Berg, Paul W.A. Janssen, Tobias Geisler, Meinrad Gawaz, Rossella Marcucci, Anna Maria Gori, Thomas Cuisset et al. · 2015 · Thrombosis and Haemostasis
32. Dual antiplatelet therapy guided by platelet function testing
    Dominick Joseph Angiolillo · 2017 · The Lancet
33. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity
    Stefanie Schüpke, Isabell Bernlochner, Tanja Morath, Siegmund Braun, Jörg Hausleiter, Steffen Massberg, Heribert Schunkert, Karl-Ludwig Laugwitz, Adnan Kastrati, Dirk Sibbing et al. · 2014 · Thrombosis and Haemostasis
34. Platelet testing in flow diversion: a review of the evidence
    L. Ian Taylor, James Charles Dickerson, Robert J. Dambrino, M. Yashar S. Kalani, Philipp Taussky, Chad W. Washington, Min S. Park · 2017 · Neurosurgical FOCUS
35. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention– a systematic review and meta-analysis
    Lanning Zhang, Jie Yang, Xiaoquan Zhu, Xuyun Wang, Li Hua Peng, Xiaoqi Li, Peng Cheng, Tong Yin · 2014 · Thrombosis Research
36. Platelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature
    Soon Tjin Lim, Catherine A. Coughlan, Stephen J. X. Murphy, Israel Fernández‐Cadenas, Joan Montaner, Vincent Thijs, Lars Marquardt, Dominick J. H. McCabe · 2015 · Platelets
37. World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI
    Glenn N. Levine, Young‐Hoon Jeong, Shinya Goto, Jeffrey L. Anderson, Yong Huo, Jessica L. Mega, Kathryn A. Taubert, Sidney C. Smith · 2014 · Global Heart
38. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study
    Gennaro Giustino, Ajay Jayant Kirtane, Usman Baber, Philippe Généreux, Bernhard Witzenbichler, Franz‐Josef Neumann, Giora Weisz, Akiko Maehara, Michael Rinaldi, Christopher Metzger et al. · 2016 · The American Journal of Cardiology
39. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI
    Claudius Jacobshagen, Lisa Groß, Dietmar Trenk, Tobias Geisler, Martin Orban, Tommaso Gori, Martin Hadamitzky, Béla Péter Merkely, Róbert Gábor Kiss, András Komócsi et al. · 2016 · Thrombosis and Haemostasis
40. Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents
    Dominick Joseph Angiolillo, José Luis Ferreiro · 2013 · American Journal of Cardiovascular Drugs
41. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention
    Jolanta Maria Siller-Matula, Carina Gruber, Marcel Francesconi, Cornelia Dechant, Bernd Jilma, Georg Delle‐Karth, Katharina Grohs, Andrea Podczeck-Schweighofer, Günter Christ · 2014 · Clinical Science
42. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation
    Zhenyang Liang, Yaling Han, Xiaolin Zhang, Yi Li, Chenghui Yan, Jian Kang · 2013 · EuroIntervention
43. The Sum of Two Evils
    Carlos G. Santos‐Gallego, Juan J. Badimón · 2014 · Journal of the American College of Cardiology
44. Genotype-based clinical trials in cardiovascular disease
    Naveen L. Pereira, Daniel J. Sargent, Michael E. Farkouh, Charanjit S. Rihal · 2015 · Nature Reviews Cardiology
45. Platelet function inhibitors and platelet function testing in neurointerventional procedures
    Chirag D. Gandhi, Ketan R. Bulsara, Johanna T Fifi, Tareq Kass‐Hout, Ryan A. Grant, Josser E Delgado Almandoz, Joey English, Philip M Meyers, Todd A. Abruzzo, Charles Joseph Prestigiacomo et al. · 2014 · Journal of NeuroInterventional Surgery
46. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study
    Derek Y F So, George A. Wells, Ruth McPherson, Marino X. Labinaz, Michel R. Le May, Christopher A. Glover, ALEXANDER J. DICK, Michael P.V. Froeschl, J. Marquis, Michael H. Gollob et al. · 2015 · The Pharmacogenomics Journal
47. Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?
    Jean‐Philippe Collet, Johannes M Mair, Mario Plebani, Béla Péter Merkely, Allan S. Jaffe, Martin Möckel, Evangelos Giannitsis, Kristian A. Thygesen, Jurriën M. ten Berg, Christian Eugen Mueller et al. · 2014 · Thrombosis and Haemostasis
48. Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)
    Michal Droppa, Dimitri Tschernow, Karin Müller, Elli Tavlaki, Athanasios Karathanos, Fabian Stimpfle, Elke Schaeffeler, Matthias Georg Schwab, Alexander Tolios, Jolanta Maria Siller-Matula et al. · 2015 · PLoS ONE
49. Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?
    Kurt Huber, Eric Bates, Marco Valgimigli, Lars C. Wallentin, Steen Dalby Kristensen, Jeffrey L. Anderson, José Luis López Sendón, Marco Tubaro U, Christopher Bull Granger, Christoph Bode et al. · 2014 · American Heart Journal
50. Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
    Małgorzata Ostrowska, Jacek Kubica, Piotr Adamski, Aldona Kubica, Ceren Eyileten, Marek A Postula, Aurel Toma, Christian Hengstenberg, Jolanta Maria Siller-Matula · 2019 · Frontiers in Cardiovascular Medicine
51. Platelet Function Testing in Contemporary Clinical and Interventional Practice
    Francesco Franchi, Fabiana Rollini, Jung Rae Cho, Elisabetta Ferrante, Dominick Joseph Angiolillo · 2014 · Current Treatment Options in Cardiovascular Medicine
52. Dual antiplatelet therapy: optimal timing, management, and duration
    Pierre François Sabouret, Sophie K. Rushton-Smith, Mathieu Kernéis, Johanne Silvain, Jean‐Philippe Collet, Gilles Montalescot · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
53. Antiplatelet drug resistance: Molecular insights and clinical implications
    Christopher Nicholas Floyd, Albert Ferro · 2015 · Prostaglandins & Other Lipid Mediators
54. Platelet Function Testing and Tailored Antiplatelet Therapy
    Paul W.A. Janssen, Jurriën M. ten Berg · 2013 · Journal of Cardiovascular Translational Research
55. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers
    Richard B. Horenstein, Rajnikanth Madabushi, Issam Zineh, Laura M. Yerges‐Armstrong, Cody J. Peer, Robert N. Schuck, William Douglas Figg, Alan R. Shuldiner, Michael A. Pacanowski · 2014 · The Journal of Clinical Pharmacology
56. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study
    for the ARCTIC investigators, Jean‐Philippe Collet, Jean‐Sébastien Hulot, Thomas Cuisset, Grégoire Rangé, Guillaume Cayla, Eric VAN BELLE, Simon Elhadad, Hélène Rousseau, Pierre François Sabouret et al. · 2015 · European Journal of Clinical Pharmacology
57. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?
    Ajay Jayant Kirtane, Puja B. Parikh, Thomas Stuckey, Ke Xu, Bernhard Witzenbichler, Giora Weisz, Michael J. Rinaldi, Franz‐Josef Neumann, David Christopher Metzger, Timothy D. Henry et al. · 2015 · JACC: Cardiovascular Interventions
58. Platelet pathophysiology, pharmacology, and function in coronary artery disease
    Homam Ibrahim, Neal S. Kleiman · 2017 · Coronary Artery Disease
59. Percutaneous coronary intervention in nonagenarians: pros and cons.
    Giuseppe Biondi‐Zoccai, Antonio Abbate, Fabrizio D’Ascenzo, Davide Giacomo Presutti, Mariangela Peruzzi, Elena Cavarretta, Antonino G. M. Marullo, Marzia Lotrionte, Giacomo Frati · 2013 · Europe PMC (PubMed Central)
60. Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery
    Sirisha Emani, David Zurakowski, Michelle D Mulone, James A. DiNardo, Cameron C. Trenor, Sitaram M. Emani · 2017 · Journal of Thoracic and Cardiovascular Surgery
61. Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome
    Sam Kafian, Fariborz Mobarrez, Håkan Wallén, Bassem A. Samad · 2014 · Platelets
62. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry
    Philipp Diehl, Katharina Schnabel, Patrick Weik, Qian Zhou, Christoph Bode, Martin Moser, Christoph B. Olivier · 2013 · Thrombosis and Haemostasis
63. Role of phenotypic and genetic testing in managing clopidogrel therapy
    Noel Chan, John W. Eikelboom, Jeffrey S. Ginsberg, Mandy N. Lauw, Thomas Vanassche, Jeffrey Ian Weitz, Jack Hirsh · 2014 · Blood
64. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials
    Steen Kristensen, Willibald Hochholzer, Franz-Josef Neumann, Dietmar Trenk · 2012 · Thrombosis and Haemostasis
65. Platelet reactivity inhuman immunodeficiency virusinfected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study
    Marie Hauguel‐Moreau, Franck Boccara, Anders C. Boyd, Joe‐Elie Salem, Delphine Brugier, Angélique Curjol, Jean‐Sébastien Hulot, Mathieu Kernéis, Sophie Galier, Ariel A. Cohen et al. · 2016 · European Heart Journal
66. Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease
    Jean‐Philippe Collet, Marco Roffi, Robert A. Byrne, Francesco Costa, Marco Valgimigli, Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC), Marco Valgimigli, Héctor Bueno, Robert A Byrne, Jean‐Philippe Collet et al. · 2017 · European Heart Journal
67. Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR)
    Anne Godiér, Delphine Garrigue, Dominique Lasne, Pierre Fontana, F Bonhomme, Collet Jp, Emmanuel de Maistre, Brigitte Ickx, Yves Gruel, Mikaël Mazighi et al. · 2018 · Anaesthesia Critical Care & Pain Medicine
68. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty
    Milan Hromádka, Zuzana J Motovska, Ota Hlinomaz, Petr Kala, František Toušek, Jiří Jarkovský, M Beranová, Pavel Jansky, Michal Svoboda, Iveta Krepelkova et al. · 2021 · Journal of Personalized Medicine
69. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents
    Jennifer Yu, Roxana Mehran, Usman Baber, Sze‐Yuan Ooi, Bernhard Witzenbichler, Giora Weisz, Michael J. Rinaldi, Franz‐Josef Neumann, David Christopher Metzger, Timothy D. Henry et al. · 2017 · Circulation Cardiovascular Interventions
70. Update on antithrombotic therapy after percutaneous coronary revascularisation
    Thomas Cuisset, Freek W.A. Verheugt, Laura Mauri · 2017 · The Lancet
71. P2Y12receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation
    Melissa V. Chan, Rebecca Knowles, Martina H. Lundberg, Arthur T. Tucker, Nura Adam Mohamed, Nicholas S. Kirkby, Paul C. J. Armstrong, Jane A. Mitchell, Timothy David Warner · 2015 · British Journal of Clinical Pharmacology
72. Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications
    Stavros Spiliopoulos · 2015 · World Journal of Cardiology
73. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)
    Cormac Thomas O'Connor, Thomas John Kiernan, Bryan P. Yan · 2017 · Expert Opinion on Drug Metabolism & Toxicology
74. Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin
    Joon‐Tae Kim, Man‐Seok Park, Kang‐Ho Choi, Ki‐Hyun Cho, Beom Joon Kim, Moon‐Ku Han, Tai Hwan Park, Sang-Soon Park, Kyung Bok Lee, Byung‐Chul Lee et al. · 2015 · Stroke
75. Is Platelet Transfusion Effective in Patients Taking Antiplatelet Agents Who Suffer an Intracranial Hemorrhage?
    Lim Beng Leong, David Kuan Peng Teng · 2015 · Journal of Emergency Medicine
76. Predictors and Outcomes of Recurrent Stent Thrombosis
    Ehrin J. Armstrong, Shiv Sab, Gagan Deep Singh, Wayland Lim, Khung Keong Yeo, Stephen W. Waldo, Mitul P. Patel, Ryan Robert Reeves, John S. MacGregor, Reginald I. Low et al. · 2014 · JACC: Cardiovascular Interventions
77. Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
    Grant C. Sorkin, Travis Michael Dumont, Michael M. Wach, Jorge Luis Eller, Maxim V. Mokin, Sabareesh Kumar Natarajan, Melissa S. Baxter, Kenneth V. Snyder, Elad I. Levy, Leo Nelson Hopkins et al. · 2013 · Journal of NeuroInterventional Surgery
78. On‐pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens
    Viviana Cavalca, Bianca Rocca, Fabrizio Veglia, Giovanna Petrucci, Benedetta Porro, Veronika A. Myasoedova, Raimondo DE CRISTOFARO, Linda Turnu, Alice Bonomi, Paola Songia et al. · 2017 · Clinical Pharmacology & Therapeutics
79. Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation
    Monica Verdoia, Chiara Sartori, Patrizia Pergolini, Matteo Nardin, Roberta Rolla, Lucia Barbieri, Alon Schaffer, Paolo Nicola Marino, Giorgio Bellomo, Harry Suryapranata et al. · 2015 · Vascular Pharmacology
80. Platelet Function and Genetic Testing
    Dominick Joseph Angiolillo, José Luis Ferreiro, Matthew J. Price, Ajay Jayant Kirtane, Gregg W. Stone · 2013 · Journal of the American College of Cardiology
81. Cost–Effectiveness Analysis of Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndrome
    Minghuan Jiang, Joyce H. S. You · 2016 · Pharmacogenomics
82. The role of anticoagulants, antiplatelet agents, and their reversal strategies in the management of intracerebral hemorrhage
    Robert F. James, Viktoras Palys, Jason Lomboy, John Richard Lamm, Scott Douglas Simon · 2013 · Neurosurgical FOCUS
83. Resistance to antiplatelet drugs: what progress has been made?
    Udaya S. Tantry, Martin G. Gesheff, Fang Liu, Kevin P. Bliden, Paul Alfred Gurbel · 2014 · Expert Opinion on Pharmacotherapy
84. Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR)
    Anne Godiér, Delphine Garrigue, Dominique Lasne, Pierre Fontana, Fanny Bonhomme, Jean‐Philippe Collet, Emmanuel de Maistre, Brigitte Ickx, Yves Gruel, Mikaël Mazighi et al. · 2019 · Archives of cardiovascular diseases
85. Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
    Georges Jourdi, Anne Godiér, Marie Lordkipanidzé, Guillaume Marquis‐Gravel, Pascale Gaussem · 2022 · Frontiers in Cardiovascular Medicine
86. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes
    Zenko Nagashima, Kengo Tsukahara, Satoshi Morita, Tsutomu Endo, Teruyasu Sugano, Kiyoshi Hibi, Hideo Himeno, Kazuki Fukui, Satoshi Umemura, Kazuo Kimura · 2013 · Journal of Cardiology
87. Coagulation Factors and Recurrence of Ischemic and Bleeding Adverse Events in Patients with Acute Coronary Syndromes
    Gianluca Calogero Campo, Rita Pavasini, Alberto Vincenzo Pollina, Matteo Tebaldi, Roberto Ferrari · 2013 · Thrombosis Research
88. Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention
    Yi Yao, Xiaofang Tang, Jiahui Zhang, Chen He, Yuan-Liang Ma, Jingjing Xu, Ying Song, Ru Liu, Xianmin Meng, Lei Song et al. · 2016 · Thrombosis Research
89. Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis
    Soon Tjin Lim, Vincent Thijs, Stephen J. X. Murphy, Israel Fernández‐Cadenas, Joan Montaner, Chika Offiah, Lars Marquardt, Peter J. Kelly, Philip M. Bath, Su‐Yin Lim et al. · 2020 · Journal of Neurology
90. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?
    Christina G. Tise, Alan R. Shuldiner · 2013 · Journal of Human Genetics
91. Why have studies of tailored anti-platelet therapy failed so far?
    Jolanta Maria Siller-Matula, Bernd Jilma · 2013 · Thrombosis and Haemostasis
92. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel
    Edward T. Carreras, Willibald Hochholzer, Andrew L. Frelinger, Francesco Nordio, Michelle L. O’Donoghue, Stephen D. Wiviott, Dominick Joseph Angiolillo, Alan D. Michelson, Marc Steven Sabatine, Jessica L. Mega · 2016 · Thrombosis and Haemostasis
93. Total Thrombus‐formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
    Yu Oimatsu, Koichi Kaikita, Masanobu Ishii, Tatsuro Mitsuse, Miwa Ito, Yuichiro Arima, Daisuke Sueta, Aya Takahashi, Satomi Iwashita, Eiichiro Yamamoto et al. · 2017 · Journal of the American Heart Association
94. Different Influences of Hematocrit on the Results of Two Point-Of-Care Platelet Function Tests, the VerifyNow Assay and Multiple Electrode Platelet Aggregometry
    Yun Gi Kim, Jung‐Won Suh, Jin Joo Park, Il‐Young Oh, Chang‐Hwan Yoon, Young‐Seok Cho, Tae‐Jin Youn, In‐Ho Chae, Dong‐Ju Choi · 2014 · PLoS ONE
95. Clopidogrel Response Variability
    Carrie S. Oliphant, Brian J. Trevarrow, Paul P. Dobesh · 2015 · Journal of Pharmacy Practice
96. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)
    Thomas O. Bergmeijer, Jean‐Luc Reny, Ruth E. Pakyz, Li Gong, Joshua P. Lewis, Eun Young Kim, Dániel Aradi, Israel Fernández‐Cadenas, Richard B. Horenstein, Ming Ta Michael Lee et al. · 2017 · American Heart Journal
97. Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation
    Seung‐Jun Lee, Jung‐Joon Cha, Young‐Hoon Jeong, Sung‐Jin Hong, Chul‐Min Ahn, Jung‐Sun Kim, Young‐Guk Ko, Donghoon Choi, Myeong‐Ki Hong, Yangsoo Jang et al. · 2022 · JACC: Cardiovascular Interventions
98. A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel
    Mark Roland Thomas, Yanushi Dullewe Wijeyeratne, Jane A. May, Andrew J. Johnson, Stan Heptinstall, Susan C. Fox · 2014 · Platelets
99. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials
    Jun Chen, Haoyu Meng, Lei Xu, Jie Liu, Deyu Kong, Pengsheng Chen, Xiaoxuan Gong, Jianling Bai, Fengwei Zou, Zhijian Yang et al. · 2014 · Journal of Thrombosis and Thrombolysis
100. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients
     Niels Straub, Andreas Beivers, Ekaterina Lenk, Dániel Aradi, Dirk Sibbing · 2013 · Thrombosis and Haemostasis